Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


4 Cephalalgia
2 Headache
1 Neurology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. RIESENBERG R, Gaul C, Stroud CE, Dong Y, et al
    Long-term open-label safety study of galcanezumab in patients with episodic or chronic cluster headache.
    Cephalalgia. 2022;42.
    PubMed         Abstract available

  2. EVERS S, Holle-Lee D, Schankin CJ, Kull P, et al
    Visual snow syndrome is probably not mediated by CGRP: A case series.
    Cephalalgia. 2022;42.
    PubMed         Abstract available

  3. LANGER LK, Bayley MT, Lawrence DW, Comper P, et al
    Revisiting the ICHD-3 criteria for headache attributed to mild traumatic injury to the head: Insights from the Toronto Concussion Study Analysis of Acute Headaches Following Concussion.
    Cephalalgia. 2022;42.
    PubMed         Abstract available

  4. RAY JC, Pham X, Foster E, Cheema S, et al
    The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature.
    Cephalalgia. 2022;42.
    PubMed         Abstract available


  5. FOFI L, Altamura C, Fiorentini G, Brunelli N, et al
    Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.
    Headache. 2022 Oct 7. doi: 10.1111/head.14400.
    PubMed         Abstract available

  6. HARPE J, Bernstein C, Harriott A
    Migraine and infertility, merging concepts in women's reproductive health: A narrative review.
    Headache. 2022 Oct 6. doi: 10.1111/head.14402.
    PubMed         Abstract available


  7. DE VRIES LENTSCH S, Heleen van der Arend BW, Maassen van den Brink A, Terwindt GM, et al
    Blood Pressure in Migraine Patients Treated With Monoclonal Anti-CGRP (receptor) Antibodies: A Prospective Follow-up Study.
    Neurology. 2022 Oct 4. pii: WNL.0000000000201008.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.